MedPath

Examination of treatment utility and advantage of taking medicine in which acknowledgment function improvement in patient with schizophrenia with new antipsychotic is made main axis

Not Applicable
Conditions
schizophrenia
Registration Number
JPRN-UMIN000005025
Lead Sponsor
Department of Psychiatry,Kobe University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

In case of patients with diabetic mellitus is excluded because Olanzapine is contraindicated drug.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath